The EORTC Board cordially invites you to a Plenary Session in honor of Francoise Meunier
At the Crowne Plaza Brussels - Le Palace on 12 March 2015 at 16:00
After 24 years of dedicated service as EORTC Director General with a major commitment to the management of pan-European cancer research, Françoise Meunier will continue her activities from 1st April 2015 as EORTC Director Special Projects.
Program
- General introduction - Roger Stupp (CH)
- Françoise Meunier’s implication in research on “Fungal infections” - Peter Donnelly (NL)
- Françoise Meunier as EORTC Director General - Alexander Eggermont (FR)
- The patients perspectives and survival issues - Isabelle Lebrocquy (NL)
- Cancer management and transatlantic cooperation - Richard Schilsky (USA)
- The EORTC Charitable Trust - Diego du Monceau de Bergendal (BE)
- EORTC future perspectives - Roger Stupp (CH)
Followed by a reception and walking dinner at Palais d’Egmont at 19:00
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
